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Objectives: Untreated obstructive sleep apnea-hypopnea syndrome (OSAHS) is associated with excessive daytime sleepiness, increased risk of cardiovascular (CV) disease, and road
traffic accidents (RTAs), which impact survival and health-related quality of life. This study, funded by the French National Authority for Health (HAS), aimed to assess the
cost-effectiveness of different treatments (i.e., continuous positive airway pressure [CPAP], dental devices, lifestyle advice, and no treatment) in patients with mild-to-moderate
OSAHS in France.
Methods: A Markov model was developed to simulate the progression of two cohorts, stratified by CV risk, over a lifetime horizon. Daytime sleepiness and RTAs were taken into
account for all patients while CV events were only considered for patients with high CV risk.
Results: For patients with low CV risk, incremental cost-effectiveness ratio (ICER) of dental devices versus no treatment varied between 32,976 EUR (moderate OSAHS) and
45,579 EUR (mild OSAHS) per quality-adjusted life-year (QALY), and CPAP versus dental devices, above 256,000 EUR/QALY. For patients with high CV risk, CPAP was associated
with a gain of 0.62 QALY compared with no treatment, resulting in an ICER of 10,128 EUR/QALY.
Conclusion: The analysis suggests that it is efficient to treat all OSAHS patients with high CV risk with CPAP and that dental devices are more efficient than CPAP for mild-to-moderate
OSAHS with low CV risk. However, out-of-pocket costs are currently much higher for dental devices than for CPAP (i.e., 3,326 EUR versus 2,430 EUR) as orthodontic treatment is
mainly non-refundable in France.
Keywords: Continuous positive airway pressure, Dental devices, Obstructive sleep apnea, Cost-effectiveness analysis
In France, obstructive sleep apnea-hypopnea syndrome (OS-
AHS) is associated with a major health and economic burden
due the relatively high prevalence of the condition (i.e., 4 per-
cent of the male adult population and 2 percent of the female
adult population) and to the increasing use of medical devices
such as continuous positive airway pressure (CPAP) (1;2). In
January 2008, the French Ministry of Health requested a re-
evaluation of the medical devices (MD) included on the list of
products and services approved for reimbursement (LPPR), for
respiratory failure. Two commissions of the French National
This project was commissioned by the Ministry of Health, funded by the HAS and undertaken by
Amaris. The technical report of this research (including the deterministic and probabilistic
analyses) is available online at www.has-sante.fr. Many thanks to the 38 experts who provided
critical advice and contribution for this project, and to the HAS (Cle´ment V., Cohen-Akenine A.,
Couilleront-Peyrondet AL., Hamers F. and Ghabri S., Leclerc, S., Pessel C.) and Amaris colleagues
(Doutriaux A., Jiang Y., Selya-Hammer C and Taieb V.) who worked on this analysis or
publication and do not appear as co-authors.
Authority for Health (HAS) worked in parallel on this multi-
ple technology assessment: (i) The National committee for the
evaluation of medical devices and health technologies (CNED-
iMTS), and its internal services, the Department of Assessment
of Medical Devices (SED), assessed the clinical benefit of the
MD in respiratory failure; and (ii) The Commission for Eco-
nomic Assessment and Public Health (CEESP), and its internal
services, the Health Economics and Public Health Department
(SEESP), assessed specifically the cost-effectiveness of theMD
in OSAHS.
OSAHS is a chronic condition characterized by the occur-
rence, during sleep, of successive episodes of cessation or de-
crease in respiratory airflow (2).Apnea and hypopnea are caused
by repetitive collapse of the upper airways thatmay be either par-
tial (hypopnea) or total (apnea). Symptoms have an important
impact on health-related quality of life (HRQoL) and include
excessive daytime somnolence, nonrefreshed sleep, nocturia,
excessive snoring, choking during sleep, morning headaches,
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Figure 1. Structure of the Markov models.
and sexual dysfunction (2). If left untreated, OSAHS can lead
to serious consequences such as increased risk of cardiovascular
(CV) disease and road traffic accidents (RTAs).
Tests such as the apnea/hypopnea index (AHI) and the Ep-
worth Sleepiness Scale (ESS) are widely used to diagnose OS-
AHS and to classify the severity of the condition (2;3). The
AHI represents the number of apnea and hypopnea events per
hour of sleep. The ESS uses a very short questionnaire and rates
the daytime sleepiness between 0 (normal) and 24 (severe). In
France, OSAHS severity relies partially on the AHI where mild
is defines as an AHI between 5 and 15, moderate between 15
and 30, and severe above 30 (1;2).
In the mild-to-moderate OSAHS population, treatment ef-
fect on CV events appears to be linked to patients’ CV comor-
bidity. Indeed, observational studies conducted tend to show
that CPAP reduces the incidence of CV only for patients with
highCV comorbidities at baseline. Over a 10-year period,Marin
et al. (4) followed over 1,000 patients with relatively few CV
comorbidities (i.e., 35 percent of patients with hypertension,
11 percent with diabetes, 8 percent with hyperlipidemia, and
8 percent with CV disease). The number of events was similar
between patients untreated and treated with CPAP. These results
differ from those found in the study by Buchner et al. (5) who,
over 6 years, followed 400 patients with a high level of CV
comorbidity (i.e., 71 percent of patients with hypertensions, 23
percent with diabetes, 60 percent with hyperlipidemia, and 8
percent with other CV disease). The results showed that CPAP
treatment significantly reduced the risk of CV events (estimated
event-free survival after 10 years was 51.8 percent in untreated
and 80.3 percent in treated patients; log-rank test, p < .001;
absolute risk reduction, 28.5 percent). Campos-Rodriguez et al.
(6) came to similar conclusions with their observational study
among female patients with high levels of CV comorbidity.
There is a lack of cost-effectiveness evaluation of treat-
ment options in patients with mild-to-moderate OSAHS. To
our knowledge, only one previous study has been published by
Weatherly et al. (7), which summarized the health technology
assessment (HTA) conducted by McDaid et al. (3).
This study, funded by the HAS, aimed to assess the cost-
effectiveness of different treatments (i.e., CPAP, dental devices,
lifestyle advice, and no treatment) for patients with mild-to-
moderate OSAHS, with low or high CV comorbidities at base-
line, in France.
MATERIALS AND METHODS
Model Structure
Themodelwas developed using theHASmethodological guide-
lines (8) and a “collective perspective.” This perspective takes
into account all direct costs borne by all healthcare payers (in-
cluding for instance complementary insurance and out of pocket
costs); it does not include indirect costs. A Markov model was
developed to simulate the progression of disease in mild-to-
moderate adult patients with OSAHS (Fig. 1). As discussed in
the introduction, in the mild-to-moderate OSAHS population,
treatment effect appears to be partially linked to patients’ CV
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comorbidity. Based on this evidence, the study population was
stratified by CV risk (4;5). Two different cohorts were, there-
fore, considered, according to the level of CV risk at baseline,
with two different corresponding model structures based on two
or four health states: Cohort 1: Patients with mild or moderate
OSAHS and low CV risk at baseline. Markov model with two
health states (OSAHS and death) and one risk of event (RTA).
All treatment strategies were compared (i.e., CPAP, dental de-
vices, lifestyle advice, and no treatment) by assessing treatment
effects on daytime sleepiness and RTAs.Cohort 2: Patients with
mild ormoderateOSAHS and highCV risk.Markovmodel with
four health states (i.e., OSAHS, OSAHS post CV event, OS-
AHS post CV event with disability and death) and three risks
of events (i.e., CV event, CV event with disability, and RTA).
CPAP, dental devices, and the absence of treatment were com-
pared by assessing treatment effects on daytime sleepiness, CV
events, and RTAs.
Patients who became disabled following a CV event were
assumed to face no further risk of RTA. Patients discontinuing
treatment were progressing according to the transition proba-
bilities associated with no treatment.
Costs and health effects, both in terms of quality-adjusted
life-years (QALY) and life-years gained (LYG), associated with
the interventions were assessed over a lifetime horizon given the
chronic nature of OSAHS, and were discounted at 4 percent per
year during the first 30 years and 2 percent per year thereafter.
Inputs
The data used to estimate the parameters of the model were
obtained from systematic reviews and meta-analyses (3;9), ob-
servational studies (5;10;11), modeling studies (3;7), and expert
opinion. All inputs are available in Table 1.
Patient Characteristics. Patient characteristics at baseline were ob-
tained from European cohort studies and the French national
database “Syste`me National Inter-re´gime de l’Assurance Mal-
adie” (SNIIRAM) (3;5). The SNIIRAM gathers all data on
reimbursed health expenditure at the national level. Fifty-five
percent of patients in the model were considered to have a
chronic long-term illness. These patients benefited from a 100
percent reimbursement rate for incurred health expenses when
applicable, versus 60 percent to 70 percent for other patients.
Daytime Sleepiness. The effect of treatment on daytime sleepiness
is reflected in the model by an improvement in HRQoL and
lower risk of injury and death due to RTAs. Treatment effect on
daytime sleepiness, assessed by a reduction of the ESS scores,
was estimated based on meta-analyses (3;9).
Cardiovascular Events. The CPAP effect on CV events is reflected
in the model by an incidence reduction, and therefore an im-
provement in HRQoL and lower risk of death. Lifetime CV risk
and excess mortality were simulated from Kaplan Meier curves
from the German study by Buchner et al. (5). The curves were
then digitalized using the GetData software and a parametric
survival function was estimated based on an exponential distri-
bution. The breakdown of CV events observed in Buchner et
al. (5) for patients regardless of OSAHS severity was applied to
mild and moderate OSAHS patients and was assumed constant
over time. Rate of debilitative stroke was taken from literature
(20).
Road Traffic Accidents. Baseline RTA riskwas estimated from a French
database (10) taking into account both the number of road fa-
talities and injuries in 2011 for the population over 45 years
old (i.e., 1,038 killed, 7,382 hospitalized, 12,769 slightly in-
jured including 85 percent, 79 percent, and 69 percent of whom
were males, respectively) and the number of people in France
with a driver’s license (40.4 million people of whom 30 per-
cent were aged 55 or older). In the model, the probability of
being killed or injured was adjusted to patient characteristics
(i.e., age and sex). Excess risk due to OSAHS was taken from
a French observational study (11) and was applied to patients
of all severity levels. The impact of CPAP on RTA was taken
from a meta-analysis (3) and no studies were identified that as-
sessed the impact of dental devices or lifestyle advice on RTA.
Therefore, an adjusted odds ratio for dental devices and lifestyle
advice compared with no treatment was estimated by applying
the ratio of the treatment effects on ESS to the odds ratio for
RTA.
Death. Crude death rates by age, sex, and cause of death were
obtained from data published by the French Institute of Health
and Medical Research (INSERM) for 2010 (12). This all-cause
mortality includes disease-specific mortality in the general pop-
ulation; therefore, a correction was applied, according to the
specific cohort.
Compliance. Compliance, defined as the long-term adherence to
medical device, was derived for CPAP from a French database
(SNIIRAM). Due to a lack of data on compliance with dental
devices and with lifestyle advice, including the literature, com-
pliance with these latter treatments was assumed to be equal to
that of CPAP.
Resource Use and Cost Estimation. Total costs, in EUR 2013, were broken
down by healthcare payer. The current study takes into account
the cost of MD and associated services as well as other health-
care resources, including any health-care use due to CV events
and RTAs. Resources associated withMDwere obtainedmainly
from the twenty experts of the working group. CV events and
RTAs resources were analyzed from French databases and a
governmental report (10). Direct costs were estimated wherever
possible on production factors, defined as the resources con-
sumed (i.e., goods, services, and time) to produce the health
care being studied. If not available, costs were estimated on
reimbursement tariffs.
The cost of dental devices was estimated as the average of
different types of devices sold in 2012 and weighted by each
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Table 1. Model Inputs
Input (measure) Value Ref
Patient characteristics at baseline
Age (years) 56 5
Sex (% male) 86 5
ESS score : mild OSAHS 7 3
ESS score : moderate OSAHS 13 3
Treatment effect on daytime sleepiness (ESS score)
CPAP versus no treatment : Mild OSAHS -1.5 3
CPAP versus no treatment : Moderate OSAHS -2.04 3
CPAP versus dental devices : Mild OSAHS -0.2 Assumption
CPAP versus dental devices : Moderate OSAHS -0.2 3
Lifestyle advice versus no treatment: Mild-to-moderate OSAHS -0.31 9
Monthly probability to have a CV event
Untreated patients 0.0043687 5, Parametric survival function : Exponential distribution)
Patients on CPAP 0.0019503 5, Parametric survival function : Exponential distribution)
Breakdown events
Coronary heart disease 65.80% 5
stroke 19.7% 5
death from CV event 14.50% 5
Rate of debilitative stroke: 30.9% 20
RTA
Excess risk due to OSAHS 2.09 11
Monthly probability to die from a RTA, if untreated OSAHS 0.0000172 3,10
Monthly probability to be injured from a RTA, if untreated OSAHS 0.0002930 3,10,11
CPAP effect (OR) 0.17 3
Dental device effect (OR) 0.19 Assumption (Calculated from ESS score)
Lifestyle advice effect (OR) 0.97 Assumption (Calculated from ESS score)
Crude death rates per 100 000 population, per sex and age
All cause, between 45 and 95+ years oldFrance mainland, 2010 (Code CIM) Not applicable 12
Cerebrovascular disease (Code CIM) I60 -I69 12
Ischemic heart disease (Code CIM) I20 -I25 12
Road traffic accident (Code CIM) V01-V99 12
Compliance
Patients continuing treatment at 6 years (%) 66 SNIIRAM
Healthcare resources used for CPAP (number per year)
Specialist visit, first year 2 Official journal
Specialist visit, subsequent year 1 Official journal
Polysomnography, first and subsequent year 1 for 15% of patient Official journal and expert opinion
Polygraphy, first year 1 for 15% of patient Official journal and expert opinion
Healthcare resources used for dental devices during its lifespan
Specialist visit, first year 2 Official journal and expert opinion
Specialist visit, subsequent year 1 Official journal and expert opinion
Dentist visit 1 Expert opinion
Orthodontist visit 10 Expert opinion
Polysomnography, first year 2 for 15% of patient Expert opinion
Polysomnography, subsequent year (number/year) 1 for 15% of patient Expert opinion
Polygraphy, first year 2 for 85% of patient Expert opinion
Polygraphy, subsequent year (number/year) 1 for 85% of patient Expert opinion
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Table 1. Continued
Input (measure) Value Ref
Unit cost, EUR (health insurance reimbursement)
Fatal CV event costs 5 914 (100%) PMSI
Non-fatal CV event costs 5 167 (100%) PMSI
Monthly CV event cost over subsequent years 263 (100%) Health insurance database
Monthly CV event cost over subsequent years, in the event of disability 329 (100%) Health insurance database
Fatal and non-fatal RTA 5,295 (100%) 10
CPAP 21.25/week (60%) Official journal
Dental device 337 (60%) Health insurance database
Polysomnography 181.53 (100%) Health insurance database
Polygraphy 119.31 (100%) Health insurance database
Specialist visit 26.19 (70%) SNIIRAM
Orthodontist visit for dental device 564 (161) Expert opinion
Dentist consultation 23 (70%) Health insurance database
Utility
ESS 0.892+ baseline ESS ∗-0.01 3
Stroke -0.145 14
Myocardial infarction or unstable angina -0.051 14
RTA 0.62 13
OSAHS, obstructive sleep apnea-hypopnea syndrome; RTA, road traffic accident; CV, cardiovascular ; ESS : Epworth Sleepiness Scale ; CPAP : Continuous Positive Airway Pressure;
PMSI, Le Programme de me´dicalisation des syste`mes d’information; MCO, Me´decine Chirurgie Obste´trique; ENCC, e´tudes nationales de couˆts a` me´thodologie commune; SNIIRAM,
Syste`me national d’information inter-re´gimes de l’Assurance maladie.
model’s annual volume sales. Other costs related to interven-
tion management were based on expert opinion and/or derived
from French databases (Table 1). The weighted average cost of
a specialist visit was based on a SNIIRAM analysis which as-
sessed the proportion of specialists who prescribe CPAP (i.e.,
50 percent lung specialist, 45 percent general practitioner, 2
percent cardiologist, 2 percent otolaryngology, and 1 percent
neurologist visit). Costs of lifestyle advice could not be as-
sessed and therefore were not included in the cost-effectiveness
analysis.
Fatal and nonfatal CV event costs were calculated from
French hospital databases “Programme de Me´dicalisation du
Syste`me d’Information” (PMSI), and applied in each cycle of
the model for fatal and nonfatal incident cases. When available,
the cost of each diagnosis related group (DRG, or “Groupe Ho-
moge`ne de Malade” (GHM)) was derived from the average cost
observed in France (“Etudes nationales de couˆts a` me´thodologie
commune” (ENCC), 2011). Hospital stays were differentiated
by whether they occurred in a public or private establishment.
The cost of a polysomnography (PSG) exam was applied fol-
lowing a nonfatal CV event based on expert opinion.
Management of patients over time following a CV event
was based on data published by the French health insurance of
patient having this chronic condition.
RTA cost was based on a governmental report (10), and was
applied for any kind of RTA, regardless of its severity.
Utility. Excessive daytime sleepiness, RTA, CV disease, and
death were considered while taking into account patient quality
of life. Due to a lack of published French data on this topic,
utilities used in the model were derived from European litera-
ture using EQ-5D questionnaires (13–15). The EQ-5D French
set of preferences values could not be applied to these studies
as patient level data were not available. Utility values used in
the model are reported in Table 1.
The models estimating the relationship between ESS and
HRQoL weights based on the EQ-5D derived by McDaid et al.
(3) was used in our analysis. The authors derived an equation
to estimate the utility value associated with daytime sleepiness
due to OSAHS.
Data for CV events were obtained from a Swedish study
by Lindgren et al. (14) who followed sixty mild and moderate
hypertensive patients over 1 year in 2003 within the ASCOT
clinical trial and estimated utility losses associated with expe-
riencing the first CV event.
The utility value for RTA was obtained from Currie et al.
(13), who used the EQ-5D questionnaire on fifty-six Welsh
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Table 2. Results: Mild-to-Moderate OSAHS
Treatment effects ICERs
Adjusted total cost, EUR
(cost refundable by
health insurance/other) LYGs Adjusted QALYs
Cost-effectiveness
(EUR/LYG) Cost-utility (EUR/QALY)
Cohort 1 : Low CV risk
No treatment 307 25.841 Mild: 13.306 / /
(307/0) Moderate: 12.335
Dental devices 7 710 25.865 Mild: 13.469 299 103 Mild: 45 579
(4 384/3 326) Moderate: 12.560 Moderate: 32 976
CPAP 13 754 25.866 Mild: 13.493 9 108 102 Mild: 256 048
(11 324/2 430) Moderate: 12.583 Moderate: 256 278
Cohort 2 : High CV risk
No treatment 22 652 25.072 11.997 / /
(22 652/0)
CPAP 28 980 25.697 12.622 10 119 10 128
(26 555/2 425)
CPAP, continuous positive airway pressure; CV, cardiovascular; ICER, incremental cost-effectiveness ratio; LYG, life-years gained; QALY, quality-adjusted life-year.
patients 6 weeks after hospitalization due to RTA. Values used
in the model are detailed in Table 1.
Analyses
Due to the paucity of literature, incremental cost-effectiveness
ratios (ICERs) for mild OSAHS and ICERs for moderate OS-
AHS could be calculated only for cohort 1 (low CV risk) when
expressed in EUR/QALY. All other results are expressed for the
pooled mild-to-moderate OSAHS population.
The robustness of results was assessed using deterministic
(DSA) and probabilistic sensitivity analyses (PSA).
The parameters tested inDSAanalysiswere treatment effect
and costs, health states utilities and costs, discount rate. Extreme
case (worst- and best-case scenario) analyses were conducted as
well as scenario analyses. For extreme scenarios, all utility val-
ues and probabilities of CV events were varied by ± 10 percent,
by 20 percent for cost of dental devices, by 25 percent for cost of
CV and RTA and by 50 percent for treatment effect on daytime
sleepiness. These variations were based on expert opinions. For
the scenario analyses, a greater difference in treatment effect
between dental devices and CPAP (-0.85 versus -0.2) was ap-
plied (3). A separate DSA assumed a longer and more realistic
3-year lifespan of dental devices based on expert opinion, rather
than 2 years, which is the legal time before reimbursement. Dis-
count rates were varied in a subsequent DSA to 2.5 percent (16)
and costs of CV events were increased by a factor of 2.3 com-
pared with the base case to take into account the three PMSI
databases: “Me´decine Chirurgie Obste´trique” (MCO), “Soins
de suite et de re´adaptation” (SSR), and “Psychiatrie” (PSY) by
means of a SNIIRAM analysis (17).
The PSA assesses the probability that each treatment rep-
resents the most cost-effective use of resources to be reported
given currently available evidence. Uncertainty in probabili-
ties and utilities were expressed in beta distributions, costs in
gamma distributions, treatment effect on daytime sleepiness by
a normal distribution, lifespan of dental device and adherence
to medical devices by a uniform distribution.
RESULTS
Base Case Analysis for Patients with Low CV Risk (Cohort 1)
For mild-to-moderate OSAHS patients with low CV risk: (i)
Dental devices and CPAP offer similar treatment benefits (i.e.,
ESS,RTA risk, compliance) but themanagement cost associated
with CPAP was 1.7 times higher than with dental devices. Total
costs over lifetime were 7,710 EUR for Dental devices and
13,754 EUR for CPAP. Therefore, CPAP versus dental devices
was associated with an ICER of 256,000 EUR per QALY and
over 9million EURper LYgained (Table 2). (ii) ICERs of dental
devices versus no treatment varied between 32,976 EUR/QALY
(moderateOSAHS) and 45,579EUR/QALY (mildOSAHS) and
the cost per LYG was up to 300,000 EUR.
While dental device was identified as the optimal strategy
from a cost-effectiveness standpoint, out-of-pocket costs were
higher for patients (i.e., 3,326 EUR versus 2,430 EUR) due
to mainly nonrefundable orthodontist care in France, including
the application of the device. The part of the total cost that is
refundable by health insurance is detailed in Table 2.
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 32:1, 2016 6
Cost-effectiveness of Treatments for OSAHS in France
Figure 2. Tornado diagram of Cohort 2 (high CV risk), CPAP vs no treatment.
Base Case Analysis for Patients with High CV Risk (Cohort 2)
Formild-to-moderateOSAHSpatientswith highCV risk, CPAP
was associated with an increase of 0.62 QALYs/LYGs com-
pared with no treatment, resulting in ICERs of 10,128 EUR
per QALY/LYG in both the cost-effectiveness and cost-utility
analysis (Table 2). It is important to note that in the base case
analysis, the treatment effect of CPAP versus no treatment was
obtained directly from an observational study (2). The efficacy
of dental devices on the prevention of CV events in mild-to-
moderate OSAHS patients has not yet been published in the
literature.
Sensitivity Analysis. According to the univariate sensitivity analyses,
the key drivers of the ICERs were parameters related to sleepi-
ness (i.e., treatment effect on ESS, utility related to ESS) and
CV inputs (i.e., cost, probability, utility). The following tor-
nado diagram (Figure 2) compares CPAP versus no treatment
in patients with high CV risk at baseline (cohort 2).
For the moderate OSAHS population with low baseline CV
risk, the ICERof dental devices versus no treatmentwas reduced
by 26 percent when the product life of the medical device was
extended by 1 additional year and increased by 25 percent when
the treatment effect associated with dental devices on daytime
sleepiness was significantly reduced (24,525 EUR/QALY and
41,065 EUR/QALY versus 32,976 EUR/QALY). Assuming a
constant discount rate of 2.5 percent reduced the ICERs by
6 percent when comparing CPAP to no treatment for cohort 2
and less than 1 percent for all other situations. For the high CV
risk population the ICER for CPAP versus no treatment resulted
in a 14 percent reduction in costs of estimated CV costs based
on three PMSI databases (MCO, HAD, PSY) with an ICER of
8,688 compared with 10,128 EUR/QALY.
The PSA showed that dental devices were the optimal strat-
egy (versus CPAP and no treatment) for thresholds ranging from
30,000 EUR to 200,000 EUR in cohort 1. In cohort 2, CPAP
(versus no treatment) reached full certainty of being the best
strategy from 38,000 EUR/QALY threshold.
DISCUSSION
The objective of the current study was to assess the cost-
effectiveness for the different treatments for OSAHS among
patients with mild-to-moderate severity in France. This cost-
effectiveness analysis together with the assessment of the clini-
cal effectiveness of OSAHS treatments will support the French
government in reimbursement decisions.
To our knowledge, this is the first cost-effectiveness analysis
of treatment of mild-to-moderate OSAHS. Despite the uncer-
tainty surrounding various input parameters mentioned above,
this analysis clearly indicates conclusions for the two cohorts.
In France, it is efficient to treat allmild-to-moderateOSAHS
patients with high CV risk with CPAP. Robust data for dental
devices in this specific cohort was not available. By assuming
an efficacy of dental devices up to 1.56 times less than that of
CPAP on the prevention of CV events, the cost-effectiveness
of dental devices would be the same as that for CPAP. Making
an assumption of similar effectiveness based on an extrapo-
lation of results reported by Anandam et al. (18), the cost-
effectiveness of dental devices becomes far superior to that of
CPAP.
For mild-to-moderate OSAHS with low CV risk, dental
devices are more efficient than CPAP. However, patient out-
of-pocket costs are currently much higher for dental devices
than for CPAP because of mainly nonrefundable orthodontic
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treatment in France. Recommending orthodontic devices as
first-line treatment for patients with mild-to-moderate OS-
AHS would require a consideration of the rate of reimburse-
ment for costs associated with administration and fitting of the
device.
The present analysis had several limitations. Due to a lack
of published data in the literature on mild-to-moderate OSAHS,
opinions of the 20 experts of the working group were requested
on some inputs, especially level of resources used with CPAP
and dental devices. Another limitation that is also present in
other modeling studies is that sex difference on disease pro-
gression and treatment effects (i.e., impact on ESS score and
CV events) could not be considered due to a lack of data on
the topic. Costs of included outcomes (RTA and CV events)
were likely underestimated, with treatment effect also underes-
timated, thus increasing the resulting ICERs. Few publications
have documented the link between the incidence of diabetes and
OSAHS, the extent to which diabetes is a risk factor or a com-
plication of OSAHS, nor the treatment effect of OSAHS on dia-
betes. Fewer studies still have focused on the mild-to-moderate
OSAHS population. As such, diabetes was not included in this
health economic model. In the analysis of patients with low
CV risk, the effectiveness of lifestyle advice could be evaluated
without estimating the resource used to reach it, or the frequency
of visits to general practitioners or nutritionists to ensure proper
follow-up. To this date, there is no proper recommendation on
duration for the management of OSAHS with lifestyle advices.
Therefore, lifestyle advices could not be assessed in this cost-
effectiveness analysis.
A systematic literature review was conducted as a first step
to develop the model structure comparing CPAP, dental devices,
and no treatment, and neithermodel took into account long-term
follow-upwith a healthcare professional for lifestyle advices.As
in other OSAHS models, the current analysis within the French
context is based on a model which takes into account treatment
effects on daytime sleepiness, RTA, and CV events. In contrast
to models previously published in the literature (3;8;15), the
present analysis: (i) focuses on mild-to-moderate OSAHS in
whom a treatment effect on CV events was only applied for
patients with high baseline CV risk, and (ii) the incidence of
CV events were modelled based on observational data from a
German study (6) evaluating CPAP versus no treatment, rather
than using risk equations based on variations of blood pres-
sure (BP). This component of the model was bolstered by the
study by Fava et al. (19) which demonstrated a lack of treatment
effect on BP in a subgroup analysis of patients with mild-to-
moderate OSAHS as opposed to patients with severe OSAHS.
Additionally, the expert advisory board for this study high-
lighted that BP could not sufficiently explain CV risk related to
OSAHS.
Only one other English study reported results by OS-
AHS severity, but only in their sensitivity analysis (3). For
patients with mild OSAHS, the ICER associated with CPAP
versus no treatment was £20,585/QALY and £9,391/QALY for
mild and moderate OSAHS patients, respectively. In our cost-
effectiveness analysis, cohort 2 results (i.e., mild-to-moderate
OSAHS with high CV risk) shows comparable results, display-
ing an ICER of 10,128 EUR/QALY for CPAP versus no treat-
ment. In the base case analysis of the English study the authors
obtained an ICER comparing CPAP with dental devices quite
low (i.e., £4,335). These results are thus difficult to compare
with those of the current French model given the populations
are not the same, neither the integration of CV comorbidities
nor the treatment effect on daytime sleepiness estimated by
different methods (AHI or ESE).
This health economic evaluation and decision tool has high-
lighted the need to treat mild-to-moderate OSAHS patients with
high CV risk with CPAP, and patients with low CV risk with
dental devices. The distinct lack of clinical data available on the
long-term efficacy of OSAHS treatments for mild-to-moderate
patients, notably dental devices and lifestyle advice, highlights
the need for further clinical studies to confirm the results of this
modeling study.
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